| IPO Date | July 14, 2025 to July 16, 2025 |
| Listing Date | July 21, 2025 |
| Face Value | ₹ 2 / Share |
| Price Band | ₹ 540 to ₹ 570 / Share |
| Lot Size | 26 Shares |
| Total Issue Size | 5,95,61,404 shares (Aggregating up to ₹3,395.00 Cr) |
| Fresh Issue | |
| Offer for Sale | |
| Employee Discount | 50 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 55,90,77,100 shares |
| Share holding post issue | 55,90,77,100 shares |
| Market Maker portion |
Anthem Biosciences Limited IPO opens on July 14, 2025, and closes on July 16, 2025.
| IPO Open Date | July 14, 2025 |
| IPO Close Date | July 16, 2025 |
| Basis of Allotment | July 17, 2025 |
| Initiation of Refunds | July 18, 2025 |
| Credit of Shares to Demat | July 18, 2025 |
| Listing Date | July 21, 2025 |
| Cut-off time for UPI mandate confirmation | July 16, 2025 |
Investors can bid for a minimum of 26 shares and in multiples thereof. The following table depicts the minimum and maximum investment by individual investors (retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | Rs.14,820 |
| Retail (Max) | 13 | 338 | Rs.192,660 |
| S-HNI (Min) | 14 | 364 | Rs.207,480 |
| S-HNI (Max) | 67 | 1,742 | Rs.992,940 |
| B-HNI (Min) | 68 | 1,768 | Rs.1,007,760 |
| HNI (Min) |
| Share Holding Pre Issue | 76.87% |
| Share Holding Post Issue | 74.68% |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not more than 50% of the Net Offer |
|
| NII (HNI) Shares Offered | Not less than 15% of the Net Offer |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not less than 35% of the Net Offer |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
Anthem Biosciences Limited was founded in 2006 and is a technology-driven and innovative Contract Research, Development, and Manufacturing Organization ("CRDMO") with fully integrated operations including drug development, manufacturing, and discovery procedures.
The business caters to a wide range of clients, including major pharmaceutical corporations worldwide and cutting-edge, up-and-coming biotech businesses.
Probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars are among the specialty fermentation-based APIs it produces.
During the six months ending September 30, 2024, the company produced intermediates and active pharmaceutical ingredients (API) for 10 marketable compounds that have been supported since their original development.
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
| KPI | Values |
|---|---|
| ROE | 20.82% |
| ROCE | 26.88% |
| Debt/Equity | 0.05 |
| RoNW | 20.82% |
| P/BV | 13.23 |
| PAT Margin (%) | 23.38% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 8.07 | 8.07 |
| P/E (x) | 70.62 | 70.62 |
Anthem Biosciences Limited No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099 Phone: +91 080 6672 400 Email: [email protected] Website: https://www.anthembio.com/ |
Kfin Technologies Limited Phone: 04067162222, 04079611000 Email: [email protected] |
Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.